دورية أكاديمية
أعرض في EDS

Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.

التفاصيل البيبلوغرافية
العنوان: Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.
المؤلفون: Reed DR; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA. drreed@wakehealth.edu., Wooster M; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Isom S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Ellis LR; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Howard DS; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Manuel M; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Dralle S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Lyerly S; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Bhave R; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Powell BL; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA., Pardee TS; Section On Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Medical Center Boulevard, Winston-Salem, NC, 27012, USA.
المصدر: Annals of hematology [Ann Hematol] 2023 Apr; Vol. 102 (4), pp. 897-906. Date of Electronic Publication: 2023 Mar 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy, Humans ; Adult ; Child, Preschool ; Infant ; Middle Aged ; Treatment Outcome ; Remission Induction ; Alemtuzumab/therapeutic use
مستخلص: Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received an adult induction and consolidation regimen derived from the CALGB 10102 trial modified without alemtuzumab. Of the 137 patients, 32 were < 40 years old, 52 were between 40 and 59, and 53 were ≥ 60 years old. Overall, 109 (79.6%) patients achieved a complete remission (< 40: 96.1%, 40-59: 86.5%, and 62.3% ≥ 60 (p = 0.0002)). Progression free survival for the entire cohort was 13.5 months and by age was 19.8 months for less than 40, 23.4 months for 40 to 59 and 6.7 months for ≥ 60; p = 0.0002. Median survival was 22.1 months for the entire cohort (32.9 months for ages < 40, 26.6 months ages 40-59, 7.8 months ≥ 60, p < 0.001).
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. (PMID: 10.1182/blood-2016-01-643569487422026980727)
Siegel RL et al (2021) Cancer Statistics, 2021. CA Cancer J Clin 71(1):7–33. (PMID: 10.3322/caac.2165433433946)
Stock W et al (2019) A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood 133(14):1548–1559. (PMID: 10.1182/blood-2018-10-881961645043130658992)
Advani AS, Hanna R (2020) The treatment of adolescents and young adults with acute lymphoblastic leukemia. Leuk Lymphoma 61(1):18–26. (PMID: 10.1080/10428194.2019.165810331452423)
Pulte D, Gondos A, Brenner H (2009) Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 113(7):1408–1411. (PMID: 10.1182/blood-2008-06-16486318974371)
Geyer MB et al (2020) Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica 106(8):2086–2094. (PMID: 10.3324/haematol.2020.2516868327717)
Larson RA et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85(8):2025–2037. (PMID: 10.1182/blood.V85.8.2025.bloodjournal85820257718875)
Rowe JM (2009) Optimal management of adults with ALL. Br J Haematol 144(4):468–483. (PMID: 10.1111/j.1365-2141.2008.07513.x19055668)
Stock W et al (2009) Alemtuzumab can be incorporated into front-line therapy of adult Acute Lymphoblastic Leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood 114(22):838–838. (PMID: 10.1182/blood.V114.22.838.838)
Charlson ME et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. (PMID: 10.1016/0021-9681(87)90171-83558716)
Seftel MD et al (2016) Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol 91(3):322–329. (PMID: 10.1002/ajh.24285476442326701142)
Larsen EC et al (2016) Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children’s oncology group study AALL0232. J Clin Oncol 34(20):2380–2388. (PMID: 10.1200/JCO.2015.62.4544498197427114587)
Siegel SE et al (2018) Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review. JAMA Oncol 4(5):725–734. (PMID: 10.1001/jamaoncol.2017.5305753439529450465)
Geyer MB et al (2017) Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 129(13):1878–1881. (PMID: 10.1182/blood-2016-11-749507537429228122741)
Huguet F et al (2018) Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol 36(24):2514–2523. (PMID: 10.1200/JCO.2017.76.819229863974)
Kim C et al (2019) Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. Leuk Lymphoma 60(6):1462–1468. (PMID: 10.1080/10428194.2018.153850530541363)
O’Brien S et al (2008) Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 113(8):2097–2101. (PMID: 10.1002/cncr.2381918720356)
Goekbuget N et al (2012) Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative Acute Lymphoblastic Leukemia (ALL): results of a prospective trial from the German Multicenter Study Group for Adult ALL (GMALL). Blood 120(21):1493–1493. (PMID: 10.1182/blood.V120.21.1493.1493)
Ribera JM et al (2016) Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res 41:12–20. (PMID: 10.1016/j.leukres.2015.11.01226686475)
Wieduwilt MJ et al (2018) A phase II study of dasatinib and dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed Ph/BCR-ABL1-positive acute lymphoblastic leukemia (Ph+ ALL): final results of alliance/CALGB study 10701. Blood 132:309. (PMID: 10.1182/blood-2018-99-120029)
Jabbour E et al (2023) Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24–e34. (PMID: 10.1016/S2352-3026(22)00319-236402146)
Litzow MR et al (2022) Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized Phase III national cooperative clinical trials network trial. Blood 140(Supplement 2):LBA-1-LBA−1. (PMID: 10.1182/blood-2022-171751)
Kantarjian H et al (2018) Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240–248. (PMID: 10.1016/S1470-2045(18)30011-129352703)
Short NJ et al (2020) Reduced-intensity chemotherapy with mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly diagnosed philadelphia chromosome-negative acute lymphoblastic leukemia: results from a phase II study. Blood 136:15–17. (PMID: 10.1182/blood-2020-138569)
Advani AS et al (2022) SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol 40(14):1574–1582. (PMID: 10.1200/JCO.21.0176635157496)
Rees MJ et al (2021) The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia. Leuk Lymphoma 62(10):2531–2534.
Gupta R et al (2020) Characteristics and trends of adult acute lymphoblastic leukemia in a large, public safety-net hospital. Clin Lymphoma Myeloma Leuk 20(6):e320–e327. (PMID: 10.1016/j.clml.2019.11.00332199763)
Deeren D et al (2020) Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland. Leuk Res 91:106334. (PMID: 10.1016/j.leukres.2020.10633432135394)
Saillard C et al (2014) Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. Leuk Lymphoma 55(9):2211–2212. (PMID: 10.3109/10428194.2013.87649724354683)
معلومات مُعتمدة: P30 CA012197 United States CA NCI NIH HHS; R01 CA197991 United States CA NCI NIH HHS; P30CA012197 United States GF NIH HHS; 1R01CA197991-01A1 United States GF NIH HHS
فهرسة مساهمة: Keywords: Acute Lymphoblastic Leukemia; Chemotherapy Treatment Regimens; Real-World Outcomes; Therapeutics
المشرفين على المادة: 3A189DH42V (Alemtuzumab)
تواريخ الأحداث: Date Created: 20230301 Date Completed: 20230313 Latest Revision: 20240829
رمز التحديث: 20240830
مُعرف محوري في PubMed: PMC10688020
DOI: 10.1007/s00277-023-05141-5
PMID: 36856803
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0584
DOI:10.1007/s00277-023-05141-5